NON-HODGKIN LYMPHOMA,B CELL
Clinical trials for NON-HODGKIN LYMPHOMA,B CELL explained in plain language.
Never miss a new study
Get alerted when new NON-HODGKIN LYMPHOMA,B CELL trials appear
Sign up with your email to follow new studies for NON-HODGKIN LYMPHOMA,B CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for cancer patients with failing kidneys
Disease control Recruiting nowThis study is testing whether a powerful cancer treatment called CAR-T therapy can be safely given to people with moderate to severe kidney problems. Researchers are adjusting the dose of the chemotherapy drugs given right before the CAR-T cells to see if it reduces serious side …
Matched conditions: NON-HODGKIN LYMPHOMA,B CELL
Phase: PHASE2 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Early trial tests 'Off-the-Shelf' cell therapy for tough lymphoma
Disease control Recruiting nowThis is an early-stage study testing a new type of cell therapy called universal CAR-T for adults with B-cell Non-Hodgkin Lymphoma that has come back or not responded to other treatments. The main goal is to check if the treatment is safe and see if it helps control the cancer. I…
Matched conditions: NON-HODGKIN LYMPHOMA,B CELL
Phase: NA • Sponsor: Bioray Laboratories • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for Tough-to-Treat lymphoma: early trial tests Next-Gen cell therapy
Disease control Recruiting nowThis early-stage study is testing the safety and finding the right dose of a new type of CAR-T cell therapy called BRL-201 for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy involves collecting a patient's o…
Matched conditions: NON-HODGKIN LYMPHOMA,B CELL
Phase: PHASE1 • Sponsor: Bioray Laboratories • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New 'Living Drug' trial offers hope for lymphoma patients out of options
Disease control Recruiting nowThis is a first-in-human study testing the safety and early effectiveness of a new cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T therapies. The main goa…
Matched conditions: NON-HODGKIN LYMPHOMA,B CELL
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC
-
New hope for patients who have run out of lymphoma treatment options
Disease control Recruiting nowThis study is testing a new drug called MEN1703 to see if it can help control aggressive B-cell lymphoma that has returned or hasn't responded to other treatments. It will be given alone to patients who have exhausted all standard options, and combined with another drug (glofitam…
Matched conditions: NON-HODGKIN LYMPHOMA,B CELL
Phase: PHASE2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC
-
Spinal fluid test could spot hidden brain cancer in lymphoma patients
Diagnosis Recruiting nowThis study is testing whether a new liquid biopsy method can better detect when aggressive B-cell lymphoma has spread to the brain and spinal cord. Researchers will compare this new test, which looks for tumor DNA in spinal fluid, against current standard diagnostic methods. The …
Matched conditions: NON-HODGKIN LYMPHOMA,B CELL
Phase: NA • Sponsor: Swiss Cancer Institute • Aim: Diagnosis
Last updated Mar 30, 2026 14:34 UTC
-
Could muscle loss predict who does best with advanced lymphoma treatment?
Knowledge-focused Recruiting nowThis study aims to understand if muscle loss or a patient's overall health status can predict how well someone responds to CAR-T cell therapy for B-cell lymphoma. Researchers will observe 130 adult patients already scheduled to receive this treatment. They will measure muscle mas…
Matched conditions: NON-HODGKIN LYMPHOMA,B CELL
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC
-
Massive italian study tracks 1500 lymphoma patients on Cutting-Edge antibody drugs
Knowledge-focused Recruiting nowThis study is observing how newer antibody treatments work for B-cell non-Hodgkin lymphoma in everyday Italian clinics. It will follow 1,500 patients already scheduled to receive these approved treatments to collect real-world data on effectiveness, side effects, and long-term ou…
Matched conditions: NON-HODGKIN LYMPHOMA,B CELL
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC